ACST Stock – (NASDAQ: ACST) is actually providing an update on the use
As required pursuant to the policies of the TSX Venture Exchange, Acasti Pharma Inc. (“Acasti or perhaps the “Company”) ACST Stock (NASDAQ: ACST – TSX V: ACST) is actually providing an update on the usage of the “at-the market” equity of its providing program.
As previously disclosed, Acasti entered into an amended as well as restated ATM sales agreement on June 29, 2020 (the “Sales Agreement”) with B. Riley FBR Inc., Oppenheimer & Co. Inc. and also H.C. Co. and Wainwright, LLC (collectively, the “Agents”), to put into practice an “at-the market” equity offering program under which Acasti might issue as well as promote from time to time the everyday shares of its having an aggregate offering price of up to seventy five dolars million in the Agents (the “ATM Program”).
ACST Stock – Pursuant to the ATM Program, as necessary pursuant to the policies of the TSX Venture Exchange (“TSXV”), since the end distributions found on January twenty seven, 2021, Acasti granted an aggregate of 20,159,229 typical shares (the “ATM Shares”) over the NASDAQ Stock Market for aggregate gross proceeds to the Company of US$21.7 huge number of. The ATM Shares had been sold at prevailing market costs averaging US$1.0747 a share. No securities had been sold in the facilities of the TSXV or, to the understanding of the Company, in Canada. The ATM Shares were offered pursuant to a U.S. registration statement on Form S-3 (No. 333 239538) as made effective on July 7, 2020, and the Sales Agreement. Pursuant to the Sales Agreement, a money commission of 3.0 % on the aggregate gross proceeds raised was given to the Agents in connection with their services. As a direct result of the latest ATM sales, Acasti has a total of 200,119,659 typical shares issued and superb as of March 5, 2021.
The extra capital raised has strengthened Acasti’s balance sheet and can provide the Company with extra flexibility in its continuous review process to enjoy as well as evaluate strategic alternatives.
About Acasti – ACST Stock
Acasti is a biopharmaceutical innovator that has historically centered on the research, commercialization and development of prescription drugs using OM3 greasy acids delivered both as free fatty acids and bound-to-phospholipid esters, created from krill oil. OM3 fatty acids have substantial clinical evidence of efficacy and safety in lowering triglycerides in patients with HTG. CaPre, or hypertriglyceridemia, an OM3 phospholipid therapeutic, was being created for people with serious HTG.
Forward Looking Statements – ACST Stock
Statements of this press release that aren’t statements of current or historical fact constitute “forward-looking information” to the meaning of Canadian securities laws as well as “forward looking statements” to the meaning of U.S. federal securities laws (collectively, “forward-looking statements”). Such forward looking statements include known and unknown risks, uncertainties, and other unknown elements that might result in the particular results of Acasti to be materially different from historical outcomes and from any future results expressed or perhaps implied by such forward-looking statements. In addition to statements which explicitly describe these types of risks as well as uncertainties, people are urged to consider statements labeled with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “potential,” “should,” “may,” “will,” “plans,” “continue”, “targeted” or any other similar expressions to be uncertain and forward-looking. Readers are cautioned not to place undue reliance on these forward looking statements, which speak just as of the day of this particular press release. Forward-looking claims in that press release include, but aren’t restricted to, information or statements about Acasti’s strategy, future operations and its review of strategic options.
The forward looking assertions found in this press release are expressly qualified in the entirety of theirs by this alerting statement, the “Special Note Regarding Forward Looking Statements” section in Acasti’s newest annual report on Form 10 K and quarterly report on Form 10-Q, which are actually available on EDGAR at www.sec.gov/edgar.shtml, on SEDAR at www.sedar.com as well as on the investor aisle of Acasti’s website at www.acastipharma.com. Many forward-looking claims in that press release exist as of the particular date of this particular press release.
ACST Stock – Acasti does not undertake to upgrade some such forward looking statements whether as a result of info which is new, future events or even otherwise, except as called for by law. The forward-looking claims contained herein are also subject typically to assumptions and risks and uncertainties that are actually described from time to time in Acasti’s public securities filings with the Securities as well as The Canadian and exchange Commission securities commissions, including Acasti’s newest annual report on Form 10-K and quarterly report on Form 10-Q under the caption “Risk Factors“.
ACST Stock – (NASDAQ: ACST) is giving an update on the use